Patents by Inventor Anders Lehmann
Anders Lehmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7964609Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.Type: GrantFiled: June 19, 2003Date of Patent: June 21, 2011Assignee: AstraZeneca ABInventors: Anders Lehmann, Jan Mattsson, Thomas M. Stormann
-
Publication number: 20100317626Abstract: The present invention is directed to the use of (3-Amino-2-fluoropropyl)phosphinic acid or an optical isomer thereof, or a pharmaceutically acceptable salt thereof, for the treatment or prevention of non-erosive reflux disease (NERD).Type: ApplicationFiled: July 24, 2008Publication date: December 16, 2010Applicant: ASTRAZENECA ABInventors: Goran Hasselgren, Anders Lehmann, Hans Rydholm
-
Patent number: 7807658Abstract: Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts, solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.Type: GrantFiled: April 7, 2006Date of Patent: October 5, 2010Assignee: AstraZeneca ABInventors: Anders Lehmann, Sverker von Unge
-
Publication number: 20090204702Abstract: In one embodiment, a computer-implemented method of managing a computer network includes installing an agent in each of a plurality of network nodes in the network. The agent may be configured to identify one or more types of network resources attached to a particular node with which the agent is associated. One or more roles may be assigned to or by the agent based, at least in part, upon the one or more types of network resources identified by the agent. Functions associated with the identified roles may be executed. Monitoring the status of each agent may also be carried out. In another embodiment, a network management system includes an agent executing within an associated network node of the network. The agent may be configured to operate so as to identify one or more types of resources attached to the network node. The agent may be assigned one or more roles based, at least in part, on an inference based upon the one or more types of attached resources identified by the agent.Type: ApplicationFiled: February 8, 2008Publication date: August 13, 2009Applicant: AUTIQ ASInventors: Robert JENSEN, Poul Hassan Agha KROGH, Anders LEHMANN
-
Publication number: 20090083840Abstract: In some aspects of the invention, a method for determining access to data stored within one or more databases is described. The method includes the aspects of receiving a user request from a user at an inference engine for access to the data, wherein the inference engine is in communication with a rules database, including one or more rules governing access rights to the data. Moreover, the method includes the aspects of creating a user credential based on the application of one or more of the rules to a identity information related to the user. Further, the method includes the aspects of comparing the created user credential and the user request at the one or more databases to determine whether the user meets the access rights for retrieving the data. Furthermore, the method includes aspects of determining an answer as to whether the access of the data is permitted or denied.Type: ApplicationFiled: September 9, 2008Publication date: March 26, 2009Applicant: Vertigo Netcare ASInventors: Robert JENSEN, Anders Lehmann
-
Publication number: 20090030896Abstract: A system and method for processing an electronic query that includes defining a set of rules accessible to an inference engine and wherein the set of rules are configured for (a) parsing the query into one or more subsequent-queries; and (b) determining whether additional information is necessary to answer each subsequent-query and, if so, (i) accessing a registry containing descriptions of one or more data resources, (ii) analyzing the descriptions of the one or more data resources to locate information responsive to the subsequent-query; and then the system and method could apply the set of rules to the information, aggregate all of the information responsive to the query, and supply an answer to the query that is compliant with the set of rules.Type: ApplicationFiled: July 22, 2008Publication date: January 29, 2009Applicant: AutIQ ASInventors: Robert JENSEN, Anders LEHMANN
-
Patent number: 7358245Abstract: The administration of cannabinoid receptor agonists for inhibition of transient lower esophageal sphincter relaxations, gastroesophageal reflux disease and regurgitation is disclosed.Type: GrantFiled: November 20, 2002Date of Patent: April 15, 2008Assignee: AstraZenca ABInventor: Anders Lehmann
-
Patent number: 7319095Abstract: The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough.Type: GrantFiled: December 13, 2005Date of Patent: January 15, 2008Assignee: AstraZeneca ABInventors: Anders Lehmann, Sverker von Unge
-
Publication number: 20070203163Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of irritable bowel syndrome (IBS).Type: ApplicationFiled: December 8, 2004Publication date: August 30, 2007Applicants: ASTRAZENECA AB, NPS PHARMACEUTICALS, INC.Inventors: Erik Lindström, Hakan Larsson, Anders Lehmann
-
Publication number: 20070123551Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.Type: ApplicationFiled: December 7, 2004Publication date: May 31, 2007Inventors: Hakan Larsson, Anders Lehmann, Erik Lindstrom
-
Publication number: 20070021393Abstract: Novel compounds of formula I, with the exception of i) the racemate of (3-amino-2-hydroxypropyl)phosphinic acid; and ii) (2R/S, 3R)-(3-amino-2-hydroxybutyl)phosphinic acid, having affinity to one or more GABAB receptors, their pharmaceutically acceptable salts; solvates and stereoisomers, as well as processes for their preparation, pharmaceutical compositions containing said therapeutically active compounds and the use of said active compounds in therapy.Type: ApplicationFiled: April 7, 2006Publication date: January 25, 2007Inventors: Anders Lehmann, Sverker Unge
-
Publication number: 20070010553Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment or prevention of cough.Type: ApplicationFiled: June 21, 2006Publication date: January 11, 2007Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.Inventor: Anders Lehmann
-
Publication number: 20060172979Abstract: The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough.Type: ApplicationFiled: December 13, 2005Publication date: August 3, 2006Inventors: Anders Lehmann, Sverker Unge
-
Publication number: 20060160777Abstract: The present invention relates to the use of GABAB receptor agonists for the treatment as well as the prevention of cough.Type: ApplicationFiled: December 13, 2005Publication date: July 20, 2006Inventors: Anders Lehmann, Sverker Unge
-
Publication number: 20060128760Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspects of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastro, esophageal reflux disease, as well as for the treatment of regurgitation and asthma.Type: ApplicationFiled: June 19, 2003Publication date: June 15, 2006Inventors: Anders Lehmann, Jan Mattson, Thomas Stormann
-
Patent number: 6919379Abstract: Novel compounds of formula (I) wherein R1 represents hydrogen; R2 represents hydroxy, fluoro, or an oxo group; R3 represents hydrogen; R4 represents hydrogen; and pharmaceutically acceptable salts, solvates, and the stereoisomers thereof, with the exception of the racemate of (3-amino-2-hydroxypropyl)sulphinic acid. The compounds are useful in therapy, especially for the treatment of reflux disease.Type: GrantFiled: June 4, 2002Date of Patent: July 19, 2005Assignee: AstraZeneca ABInventors: Kevin Fitzpatrick, William Geiss, Anders Lehmann, Gunnel Sundén, Sverker Von Unge
-
Publication number: 20040266861Abstract: The present invention relates to the use of cannabinoid receptor agonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of cannabinoid receptor agonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation such as regurgitation in infants, lung disease, chronic laryngitis and asthma.Type: ApplicationFiled: May 20, 2004Publication date: December 30, 2004Inventor: Anders Lehmann
-
Publication number: 20040152775Abstract: Novel compounds of formula (I) wherein R1 represents hydrogen; R2 represents hydroxy, fluoro or an oxo group; R3 represents hydrogen; R4 represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomers thereof, with the exception of the racemate of (3-amino-2-hydroxypropyl)sulphinic acid. The compounds are useful in therapy, especially for the treatment of reflux disease. The invention is also related to processes for their preparation, intermediates of said process and pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.Type: ApplicationFiled: January 13, 2004Publication date: August 5, 2004Inventors: Kevin Fitzpatrick, William Geiss, Anders Lehmann, Gunnel Sunden, Sverker Von Unge
-
Patent number: 6664069Abstract: The present invention relates to the use of GABAB receptor agonists for the inhibition of transient lower esophageal sphincter relaxations, and for the treatment of gastro-esophageal reflux disease.Type: GrantFiled: September 8, 2000Date of Patent: December 16, 2003Assignee: AstraZeneca ABInventors: Paul L. R. Andrews, Anders Lehmann
-
Patent number: 6117908Abstract: The present invention relates to the use of GABA.sub.B receptor agonists for the inhibition of transient lower esophageal sphincter relaxations, and for the treatment of gastro-esophageal reflux disease.Type: GrantFiled: November 12, 1997Date of Patent: September 12, 2000Assignee: Astra AktiebolagInventors: Paul L. R. Andrews, Anders Lehmann